Restrictive versus liberal transfusion in cardiac surgery
Which transfusion threshold best balances oxygen delivery and transfusion exposure in cardiac surgery? Compare trial populations, ischemic outcomes, mortality, and the actual thresholds used—not anemia alone.
Published studies
Open in feedRecent evidence appears first, ordered by publication date. Earlier evidence and papers without precise dates follow separately. Design categories are inferred from PubMed metadata, not evidence grades.
Showing 4 of 10 · Other
Recent evidence · past year
-
Cell salvage volume and hemostatic changes in cardiac surgery: A retrospective cohort study using routine coagulation and viscoelastic assessment.
AI summary of the abstract, unverified
- Retrospective cohort of adult cardiac surgery patients using cell salvage, analyzed as a routine coagulation cohort (N = 677) and an exploratory viscoelastic cohort (N = 50).
- Exposure was cell salvage reinfusion volume, with paired hemostatic measurements before and after and no coagulation-affecting blood products between them.
- In the routine coagulation cohort, CS volume was not significantly associated with absolute changes in any parameter (all p ≥ 0.144).
- In the viscoelastic cohort, higher CS volume was associated with lower functional fibrinogen clot strength (CFF MA β = -3.31 mm/L; 95% CI -5.53 to -1.08; adjusted p = 0.031), while the CK MA association did not survive correction.
Original abstract (PubMed)
BACKGROUND: Intraoperative cell salvage (CS) reduces allogeneic transfusion in cardiac surgery, but the washing process removes coagulation factors and platelets, raising hemostatic concerns. The dose-response relationship between CS volume and perioperative hemostatic changes remains poorly characterized. METHODS: In this retrospective study of adult patients undergoing cardiac surgery with CS use, two cohorts with paired hemostatic measurements were identified: a routine coagulation cohort (primary analysis) and a viscoelastic cohort (exploratory analysis). Both cohorts were restricted to patients without coagulation-affecting blood products between measurements. Multivariable linear regression examined CS volume and absolute changes in each parameter, adjusted for surgical and patient characteristics and baseline values. RESULTS: In the routine coagulation cohort (N = 677; median CS 0.5 L, range 0.1-1.6 L), CS volume was not significantly associated with absolute changes in any parameter (all p ≥ 0.144). In the viscoelastic cohort (N = 50; median CS 0.8 L, range 0.2-3.7 L), CS volume was significantly associated with decreased functional fibrinogen clot strength (CFF MA: β = -3.31 mm/L; 95% CI: -5.53, -1.08; p = 0.004) and overall clot strength (CK MA: β = -2.93 mm/L; 95% CI: -5.73, -0.13; p = 0.041); after Holm correction for multiple testing, the CFF MA association remained significant (adjusted p = 0.031), whereas the CK MA association did not (adjusted p = 0.244). CONCLUSIONS: At observed reinfusion volumes, CS was not associated with changes in routine coagulation parameters, but in the exploratory viscoelastic cohort, higher CS volume was associated with lower functional fibrinogen clot strength. These findings highlight the potential value of viscoelastic monitoring when higher volumes are anticipated.
-
An Integrated ERAS-PBM Pathway for Cardiac Surgery: Insights and Outcomes.
AI summary of the abstract, unverified
- This single-center, retrospective before-after study compared 229 elective cardiac surgery patients on an ERAS-PBM pathway with 162 pre-ERAS patients from 2019.
- The ERAS-PBM pathway added preoperative anemia screening and treatment, adherence to restrictive transfusion thresholds, blood conservation, and care bundles run by an ERAS nurse.
- RBC transfusion fell from 38.9% to 23.6% (p = 0.0012), and the exploratory adjusted OR for transfusion was 0.59 (95% CI 0.36-0.98; p = 0.041).
- Complications fell from 66.7% to 46.3% and hospital stay shortened from 12 to 9 days, and the authors call for larger multicenter prospective studies.
Original abstract (PubMed)
Background/Objectives: Anemia is a common condition in cardiac surgery and is strongly associated with adverse outcomes, including higher transfusion requirements, increased morbidity, and prolonged hospital stay. Enhanced Recovery After Surgery (ERAS) and Patient Blood Management (PBM) are both multimodal strategies designed to improve perioperative care. This study evaluates the impact of integrating ERAS and PBM with preoperative anemia management into a single standardized pathway in elective cardiac surgery. Methods: We conducted a retrospective, single-center before-after study at Lausanne University Hospital, comparing a pre-ERAS cohort (2019) with a prospective cohort managed under the ERAS-PBM pathway (May 2023-November 2024). The ERAS-PBM pathway included systematic preoperative anemia screening and treatment, reinforcement of adherence to existing restrictive transfusion thresholds, optimized blood conservation techniques, and standardized perioperative care bundles coordinated by a dedicated ERAS nurse. The primary outcome was the rate of red blood cell (RBC) transfusions during hospitalization. Secondary outcomes included overall transfusion rates, hemoglobin levels, complications, and length of stay. Results: A total of 391 patients were included (ERAS, n = 229; pre-ERAS, n = 162). RBC transfusion rates were significantly lower in the ERAS group (23.6% vs. 38.9%, p = 0.0012), with a reduction in the number of units per patient (p = 0.0005). Hemoglobin at admission was higher in the ERAS cohort (139.5 vs. 134 g/L, p = 0.0009). Overall complication rates decreased (46.3% vs. 66.7%, p < 0.0001), including major adverse cardiovascular events and pulmonary complications. Hospital stay was shorter (9 vs. 12 days, p < 0.0001), as was mechanical ventilation time (0 vs. 2.1 h, p < 0.0001). Anemic patients at admission were more transfused (39.3% vs. 18.6%, p = 0.002). Within the ERAS group, RBC transfusion was associated with higher rates of selected postoperative complications and longer ICU and hospital stays. In an exploratory multivariable logistic regression analysis, ERAS-PBM implementation was associated with lower odds of RBC transfusion during hospitalization (adjusted OR 0.59, 95% CI 0.36-0.98; p = 0.041). Conclusions: The integration of ERAS and PBM into a single multimodal pathway was associated with significant reductions in transfusion rates, complications, and length of stay in elective cardiac surgery. Anemia at admission and perioperative transfusion were associated with worse outcomes, emphasizing the importance of anemia management. Larger, multicenter prospective studies are warranted to confirm these results and to optimize anemia correction strategies, including earlier treatment of iron deficiency and outpatient erythropoietin use.
-
The TIMELESS Project: A Mixed-Methods Analysis of Modifiable Risk Factors and Transfusion Practices in 24,000 Cardiac Surgical Cases.
AI summary of the abstract, unverified
- A mixed-methods quality initiative at one high-volume cardiac surgery center combined a retrospective review of 24,005 adult patients (2018–2024) with a survey of 112 of 258 providers.
- The retrospective analysis examined modifiable risk factors, including preoperative anemia, malnutrition, hypothermia, hyperglycemia, and antifibrinolytic use, and their association with transfusion.
- Transfusion occurred in 55.9% of patients; preoperative anemia (IRR 1.74, 95% CI 1.67-1.83) and hypothermia (IRR 1.66, 95% CI 1.59-1.73) were linked to higher risk-adjusted transfusion, while antifibrinolytics were linked to less (IRR 0.90, 95% CI 0.86-0.93).
- Many transfusions were given without laboratory guidance (RBC 32.1%, plasma 82.4%), and 81% of responding providers endorsed a restrictive hemoglobin threshold of under 7.5 g/dL for stable patients.
Original abstract (PubMed)
BACKGROUND: Approximately 10% to 15% of all red blood cell (RBC) transfusions in the United States and United Kingdom occur during cardiac surgery. Despite efforts to standardize patient blood management, transfusion practices remain highly variable across providers and institutions. We launched the Transfusion Improvement to Minimizing Excess in Cardiac Surgery (TIMELESS) initiative to identify modifiable drivers of transfusion at our high-volume cardiac surgery center. METHODS: Our mixed-methods approach combined a retrospective data review and a survey to assess perioperative RBC and blood component (platelets, plasma, cryoprecipitate) transfusion through three key domains: (1) preoperative assessment/optimization (evaluation of modifiable risk factors for transfusion: preoperative anemia, malnutrition, anticoagulant/platelet inhibitor use); (2) perioperative blood conservation (modifiable risk factors: intraoperative antifibrinolytic use, hyperglycemia, perioperative hypothermia); (3) transfusion behaviors (laboratory guidance and transfusion triggers). These domains were investigated through (i) a retrospective database analysis that examined the association of risk factors with total intraoperative and early postoperative blood product transfusion in adult cardiac surgical patients between January 2018 and June 2024; and (ii) a structured front-line provider survey that examined opinions and behaviors that drive blood transfusion (including transfusion thresholds, triggers, and barriers to laboratory-guided practice) in anesthesia, surgical, and intensive care unit caregivers. RESULTS: Of 24,005 cardiac surgical patients in the database review, 13,420 (55.9%) received transfusions during surgery and/or early postoperatively. Of 258 front-line providers surveyed, 112 (43%) responded. Preoperative assessment/optimization (domain #1) and perioperative blood conservation (#2) found that five of six modifiable factors were associated with greater risk-adjusted transfusion: preoperative anemia (incidence rate ratio [IRR] 1.74, 95% confidence interval [CI], 1.67-1.83), malnutrition (IRR 1.44, 95% CI, 1.36-1.54), perioperative hypothermia (IRR 1.66, 95% CI, 1.59-1.73), and hyperglycemia (IRR 1.02 per 10 mg/dL, 95% CI, 1.02-1.02), whereas antifibrinolytic therapy was associated with reduced transfusion (IRR 0.90, 95% CI, 0.86-0.93). Transfusion triggers/laboratory guidance (#3) found that many transfusions were given empirically without laboratory-guidance (RBC 32.1%, platelets 44.9%, cryoprecipitate 55.0%, plasma 82.4%). Survey found that most providers (91/112, 81%) endorsed restrictive hemoglobin thresholds (<7.5 g/dL) for stable, non-bleeding patients; platelet and cryoprecipitate transfusion thresholds varied by specialty; laboratory-guidance was omitted for urgent bleeding/coagulopathy (99/112, 88%), prolonged surgical time (49/112, 44%), and long laboratory turnaround time (49/112, 44%). CONCLUSIONS: This large mixed-methods quality initiative identified modifiable risk factors, provider opinions, and transfusion behaviors to understand key drivers of transfusion in our cardiac surgery center. These results lay the groundwork to modify risk factors and transfusion behaviors and ultimately optimize perioperative blood transfusion therapy.
Earlier evidence / dates not confirmed
Includes older studies, year-only dates, and future-dated records. Inclusion does not imply landmark status.
-
Red blood cell transfusion practices in two surgical intensive care units: a mixed methods assessment of barriers to evidence-based practice.
AI summary of the abstract, unverified
- Mixed-methods study in two Baltimore ICUs (cardiac surgical and surgical), combining 52 observed patient encounters, provider surveys, and chart review.
- No intervention was tested; the authors compared prescribers with bedside nurses on their views of the ideal pretransfusion hemoglobin and on actual practice.
- Prescribers in both units (87% and 90%) more often than nurses (8% and 42%) named 7 g/dL or lower as ideal for nonbleeding patients (p = 0.002 and 0.015).
- The authors concluded that knowledge gaps, overly optimistic views of current practice, and variable thresholds between prescribers are barriers, and that targeted interventions are needed.
Original abstract (PubMed)
BACKGROUND: Despite evidence supporting restrictive red blood cell (RBC) transfusion thresholds and the associated clinical practice guidelines, clinical practice has been slow to change in the intensive care unit (ICU). Our aim was to identify barriers to conservative transfusion practice adherence. STUDY DESIGN AND METHODS: A mixed-methods study involving observation of prescriber (i.e., physicians, physician assistants, nurse practitioners) and bedside nurse daily bedside rounds, provider survey, and medical record abstraction was conducted in one cardiac surgical ICU (CSICU) and one surgical ICU (SICU) in an academic hospital in Baltimore, Maryland. RESULTS: Of 52 patient encounters observed during bedside rounds, 38 (73%) involved patients without evidence of active bleeding or cardiac ischemia. Surveys were completed by 52 (93%) of the 56 providers participating in rounds. Prescribers in the CSICU and SICU (87 and 90%, respectively) indicated the ideal pretransfusion hemoglobin (Hb) to be not more than 7 g/dL in nonbleeding and/or nonischemic patients compared to a minority of nurses (8% [p = 0.002] and 42% [p = 0.015], respectively). Prescribers and nurses in both ICUs overestimated the typical pretransfusion Hb in their units (CSICU, p < 0.001; SICU, p = 0.019). During rounds, providers infrequently explicitly discussed Hb monitoring or transfusion thresholds (33%) despite most (60%) reporting significant variation in transfusion thresholds between individual prescribers. CONCLUSIONS: Our study identified several provider and system barriers to evidence-based transfusion practices including knowledge differences, overly optimistic estimates of current practice, and heterogeneous transfusion practice in each ICU. Further work is necessary to develop targeted interventions to improve evidence-based RBC transfusion practices.
Ongoing registrations
From ClinicalTrials.govRegistrations, not results. These registry entries describe ongoing studies, not their findings. They are not counted as published evidence above; check linked records for updates and associated publications.
No registered ongoing trials found.